Bios Health Group has entered the life sciences market. This new company entity is a strategic partner providing solutions for life science companies and investors. It offers strategies to attract funding, optimize clinical development, and create effective commercial strategies. Bios Health Group also serves as a venture partner providing investor preparation for Bbotech companies seeking investment funding and access to venture funds through its investor networks.
Bios Health Group Chief Executive Officer, Zizi Uzezi Imatorbhebhe, MBA MS PMP® said in a press release, "We are thrilled to bring this comprehensive suite of end-to-end solutions to biotech and life science companies. Our strategic approach involves engagement with venture capitalists and investors, effectively addressing the funding gap that often impedes early-stage biotech companies from accessing critical financial resources required to realize their innovative concepts. Additionally, we provide established companies with proven commercial strategies to launch new products and expand their market presence."
Bios Health Group offers four strategic solutions:
Bios Health Group Enters the Market to Offer Investment-Driven and Clinical Development Optimization Strategies for Biotech and Life Science Companies. (2023, August 15). Cision PR Newswire.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.